export default [
  {
    section: "KRAS G12C",
    chapters: [
      {
        header: "KRAS G12C",
        text: "",
      },
    ],
  },
  {
    section: "KRAZATI DESIGN",
    chapters: [
      {
        header: "KRAZATI is optimized to address the relentlessness of KRAS G12C",
        text: "",
      },
    ],
  },
  {
    section: "MASTER SWITCH",
    chapters: [
      {
        header: "A master switch",
        text: "KRAS proteins work as on/off switches. When bound to GTP, the protein turns on, activating cell growth and survival.",
      },
      {
        header: "A master switch",
        text: "KRAS G12C mutation leads to aberrant signaling and uncontrolled cellular proliferation.",
      },
      {
        header: "A master switch",
        text: "Continuous signaling and continuous regeneration: Abnormal KRAS proteins continuously regenerate every 24-48 hours, which can further sustain uncontrolled cell growth.",
      },
      {
        header: "A master switch",
        text: "There is a need to continuously control the target",
      },
    ],
  },
  {
    section: "INHIBITION",
    chapters: [
      {
        header: "Selective, irreversible inhibition",
        text: "KRAZATI covalently binds to the mutant cysteine in KRAS G12C and locks the protein in its inactive, GDP-bound state.",
      },
    ],
  },
  {
    section: "CYS-12",
    chapters: [
      {
        header: "CYS-12",
        text: "",
      },
    ],
  },
  {
    section: "CNS PENETRANT",
    chapters: [
      {
        header: "CNS penetrant",
        text: "KRAZATI has a higher Kp,uu value than osimertinib, a strong CNS penetrant*",
      },
    ],
  },
  {
    section: "HALF-LIFE",
    chapters: [
        {
          header: "Longest half-life available of any KRAS G12C inhibitor*",
          text: "KRAZATI has a nearly 24-hour 15) half-life that allows drug levels to be maintained above the target threshold for continuous inhibition of signaling*â€ ",
        },
      ],
  },
];
